Figure 7.
CRL inactivation via ROC1/RBX1 siRNA silencing inhibits angiogenic activity of HUVECs. HUVECs were transfected with siROC1 or siControl and subjected to the capillary tube formation assay (a), transwell migration assay (b), PI staining and FACS analysis (c), PARP activation detection (d), ATPlite cell viability assay (e) and IB analysis of indicated proteins (f). Data was presented as mean±S.E.M. **P<0.01 and ***P<0.001